$1.53
+0.00 (+0.00%)
Open$1.53
Previous Close$1.53
Day High$1.55
Day Low$1.46
52W High$12.25
52W Low$1.40
Volume—
Avg Volume865.5K
Market Cap102.53M
P/E Ratio—
EPS$-2.08
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+4,169.9% upside
Current
$1.53
$1.53
Target
$65.33
$65.33
$48.23
$65.33 avg
$96.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 102.93M | 108.44M | 88.87M |
| Net Income | -18,276,199 | -22,730,064 | -15,420,094 |
| Profit Margin | -17.8% | -21.0% | -17.4% |
| EBITDA | -27,166,221 | -28,388,210 | -21,820,067 |
| Free Cash Flow | -19,844,248 | -21,752,544 | -13,746,863 |
| Rev Growth | +6.4% | +6.6% | +8.6% |
| Debt/Equity | 0.41 | 0.31 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |